Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764326 | 0.82 | HTR4 (0.53) | HTR4NR4A2 | |
| SCHEMBL6761915 | 0.80 | HTR4 (0.49) | HTR4NR4A2 | |
| SCHEMBL6177040 | 0.78 | HTR4 (0.49) | HTR4NR4A2 | |
| SCHEMBL6177408 | 0.78 | HTR4 (0.51) | HTR4 | |
| SCHEMBL6770723 | 0.78 | HTR4 (0.60) | HTR4 | |
| SCHEMBL6175791 | 0.76 | HTR4 (0.49) | HTR4 | |
| SCHEMBL6615450 | 0.75 | HTR4 (0.48) | HTR4NR4A2 | |
| SCHEMBL6767167 | 0.73 | KCNH2 (0.62) | HTR4NR4A2 | |
| SCHEMBL6177156 | 0.73 | HTR4 (0.59) | HTR4 | |
| SCHEMBL6328537 | 0.72 | HTR4 (0.55) | HTR4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR4 1/4885NR4A2 115/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | HTR4 2/4885NR4A2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.